The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors
Open accessAbstract
IMPORTANCE: Molecular aberrations in the phosphatidylinositol-3-kinase (PI3K) pathway drive tumorigenesis. Frequently co-occurring alterations in hormone receptors and/or human epidermal growth factor receptor 2 (HER2) may be relevant to mechanisms of response and resistance. OBJECTIVE: To identify patterns of aberration in the PI3K and interactive pathways that might lead to targeted therapy opportunities in clinical practice. DESIGN, SETTING, AND PARTICIPANTS: From January 2013 through December 2014, 19 784 consecutive tumor samples (>40 cancer types) were sent from thousands of clinicians in 60 countries to a single commercial laboratory for molecular profiling, including next generation sequencing, protein expression (immunohistochemical analysis [IHC]), and gene amplification (fluorescent in situ hybridization or chromogenic in situ hybridization). MAIN OUTCOMES AND MEASURES: Patterns in targetable genomic and proteomic alterations in the PI3K pathway and coincidence with hormone receptor and HER2 alterations. EXPOSURES: Molecular profiling across solid tumors. RESULTS: Overall, 38% of patients had an alteration in 1 or more PI3K pathway components, most commonly phosphatase and tensin homologue (PTEN) loss (by IHC) (30% of all patients), followed by mutations in PIK3CA (13%), PTEN (6%), or AKT1 (1%). Seventy percent of patients with endometrial cancer and more than 50% of patients with breast, prostate, anal, hepatocellular, colorectal, and cervical cancer exhibited alterations in at least 1 PI3K pathway gene and/or gene product. Examples of frequent aberrations included PTEN loss in hepatocellular (57% of patients), colorectal (48%), gastric (36%), prostate (52%), and endometrial cancer (49%); PIK3CA mutations in endometrial (37%), breast (31%), cervical (29%), and anal cancer (27%). PIK3CA, PTEN, and AKT1 mutations occurred more frequently in the presence of hormone receptor overexpression (androgen, progesterone, or estrogen receptor). PIK3CA mutations were also more common in the HER2-positive than in the HER2-negative group; the opposite pattern was seen for PTEN mutation or PTEN loss. CONCLUSIONS AND RELEVANCE: PI3K pathway aberrations are among the most common in cancer. They do not segregate by classic cancer histologic characteristics. Patterns of biomarker coalterations involving HER2 and hormone receptors may be important for optimizing combination treatments across cancer types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Comprehensive genomic characterization of head and neck squamous cell carcinomas
The Cancer Genome Atlas Network (2015) · Nature · doi:10.1038/nature14129 · Cited by 3,877
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,710
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Synthesis and Function of 3-Phosphorylated Inositol Lipids
Vanhaesebroeck, B., Leevers, S. J., Ahmadi, K., Timms, J., Katso, R., Driscoll, P. C., Woscholski, R., Parker, P. J., & Waterfield, M. D. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.535 · Cited by 1,535
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Pao, W., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & Varmus, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,516
Emerging landscape of oncogenic signatures across human cancers
Ciriello, G., Miller, M. L., Aksoy, B. A., Senbabaoglu, Y., Schultz, N., & Sander, C. (2013) · Nature Genetics · doi:10.1038/ng.2762 · Cited by 1,378
Le Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00188-6 · Cited by 1,137
Saal, L. H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., Mansukhani, M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 875
Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival
Liao, X., Lochhead, P., Nishihara, R., Morikawa, T., Kuchiba, A., Yamauchi, M., Imamura, Y., Qian, Z. R., Baba, Y., Shima, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207756 · Cited by 843
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
Hollander, M. C., Blumenthal, G. M., & Dennis, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3037 · Cited by 794
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.
Cairns, P., Okami, K., Halachmi, S., Halachmi, N., Esteller, M., Herman, J. G., Jen, J., Isaacs, W. B., Bova, G. S., & Sidransky, D. (1997) · PubMed · Cited by 700
Pten Dose Dictates Cancer Progression in the Prostate
Trotman, L. C., Niki, M., Dotan, Z. A., Koutcher, J. A., Di Cristofano, A., Xiao, A., Khoo, A. S., Roy-Burman, P., Greenberg, N. M., Dyke, T. V., et al. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000059 · Cited by 676
The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations
Huang, C.-H., Mandelker, D., Schmidt-Kittler, O., Samuels, Y., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., Gabelli, S. B., & Amzel, L. M. (2007) · Science · doi:10.1126/science.1150799 · Cited by 560
Oncogenic PI3K and its role in cancer
Samuels, Y., & Ericson, K. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000198021.99347.b9 · Cited by 521
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas
Lee, J. W., Soung, Y. H., Kim, S. Y., Lee, H. W., Park, W. S., Nam, S. W., Kim, S. H., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2005) · Oncogene · doi:10.1038/sj.onc.1208304 · Cited by 506
HER2 expression status in diverse cancers: review of results from 37,992 patients
Yan, M., Schwaederle, M., Arguello, D., Millis, S. Z., Gatalica, Z., & Kurzrock, R. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9552-6 · Cited by 483
Self-citationHuse, J. T., Brennan, C., Hambardzumyan, D., Wee, B., Pena, J., Rouhanifard, S. H., Sohn-Lee, C., le Sage, C., Agami, R., Tuschl, T., et al. (2009) · Genes & Development · doi:10.1101/gad.1777409 · Cited by 431
Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers
Levine, D. A., Bogomolniy, F., Yee, C. J., Lash, A., Barakat, R. R., Borgen, P. I., & Boyd, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2142 · Cited by 422
Cancer-specific mutations in PIK3CA are oncogenic in vivo
Bader, A. G., Kang, S., & Vogt, P. K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510857103 · Cited by 420
Transformation of Chicken Cells by the Gene Encoding the Catalytic Subunit of PI 3-Kinase
Chang, H. W., Aoki, M., Fruman, D., Auger, K. R., Bellacosa, A., Tsichlis, P. N., Cantley, L. C., Roberts, T. M., & Vogt, P. K. (1997) · Science · doi:10.1126/science.276.5320.1848 · Cited by 412
Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit
Miled, N., Yan, Y., Hon, W.-C., Perisic, O., Zvelebil, M., Inbar, Y., Schneidman-Duhovny, D., Wolfson, H. J., Backer, J. M., & Williams, R. L. (2007) · Science · doi:10.1126/science.1135394 · Cited by 410
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.
Soria, J., Lee, H., Lee, J. I., Luo, W., Issa, J. J., Kemp, B. L., Liu, D. D., Kurie, J. M., Mao, L., & Khuri, F. R. (2002) · PubMed · Cited by 406
Di Nicolantonio, F., Arena, S., Tabernero, J., Grosso, S., Molinari, F., Macarulla, T., Russo, M., Cancelliere, C., Zecchin, D., Mazzucchelli, L., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci37539 · Cited by 343
Janku, F., Wheler, J. J., Naing, A., Falchook, G. S., Hong, D. S., Stepanek, V. M., Fu, S., Piha-Paul, S. A., Lee, J. J., Luthra, R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1726 · Cited by 300
Self-citationAssessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
Janku, F., Hong, D. S., Fu, S., Piha-Paul, S. A., Naing, A., Falchook, G. S., Tsimberidou, A. M., Stepanek, V. M., Moulder, S. L., Lee, J. J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2013.12.035 · Cited by 237
Self-citationAnalysis of PTEN and the 10q23 region in primary prostate carcinomas
Feilotter, H. E., Nagai, M. A., Boag, A. H., Eng, C., & Mulligan, L. M. (1998) · Oncogene · doi:10.1038/sj.onc.1200205 · Cited by 230
Somatic mutation and gain of copy number of PIK3CA in human breast cancer
Wu, G., Xing, M., Mambo, E., Huang, X., Liu, J., Guo, Z., Chatterjee, A., Goldenberg, D., Gollin, S. M., Sukumar, S., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1262 · Cited by 228
Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas.
Wang, S. I., Parsons, R. E., & Ittmann, M. (1998) · PubMed · Cited by 218
HER2 aberrations in cancer: Implications for therapy
Yan, M., Parker, B. A., Schwab, R., & Kurzrock, R. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.02.008 · Cited by 210
Self-citationHanker, A. B., Pfefferle, A. D., Balko, J. M., Kuba, M. G., Young, C. D., Sánchez, V., Sutton, C. R., Cheng, H., Perou, C. M., Zhao, J. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303204110 · Cited by 203
Regulation of the p85/p110α Phosphatidylinositol 3′-Kinase
Yu, J., Wjasow, C., & Backer, J. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30199 · Cited by 181
Franz, D. N., Belousova, E., Sparagana, S., Bebin, E. M., Frost, M., Kuperman, R., Witt, O., Kohrman, M. H., Flamini, J. R., Wu, J. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70489-9 · Cited by 179
Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor
Mallon, R., Feldberg, L. R., Lucas, J., Chaudhary, I., Dehnhardt, C., Santos, E. D., Chen, Z., dos Santos, O., Ayral-Kaloustian, S., Venkatesan, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1694 · Cited by 172
Genomic Rearrangements of PTEN in Prostate Cancer
Phin, S., Moore, M. W., & Cotter, P. D. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00240 · Cited by 158
Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN
Gray, I., Stewart, L., Phillips, S. M. A., Hamilton, J., Gray, N. E., Watson, G., Spurr, N., & Snary, D. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.674 · Cited by 154
Templeton, A. J., Dutoit, V., Cathomas, R. L., Rothermundt, C. A., Bärtschi, D., Droege, C., Gautschi, O. P., Borner, M., Fechter, E., Stenner, F., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.03.040 · Cited by 140
PTEN/MMAC1/TEP1 involvement in primary prostate cancers
Pesche, S., Latil, A., Muzeau, F., Cussenot, O., Fournier, G., Longy, M., Eng, C., & Lidereau, R. (1998) · Oncogene · doi:10.1038/sj.onc.1202081 · Cited by 131
Luminal Expression of PIK3CA Mutant H1047R in the Mammary Gland Induces Heterogeneous Tumors
Meyer, D. S., Brinkhaus, H., Müller, U., Müller, M., Cardiff, R. D., & Bentires‐Alj, M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3827 · Cited by 125
Post-translational regulation of PTEN
Wang, X., & Jiang, X. (2008) · Oncogene · doi:10.1038/onc.2008.242 · Cited by 113
Ray-Coquard, I., Favier, L., Weber, B. E., Roemer-Bécuwe, C., Bougnoux, P., Fabbro, M., Floquet, A., Joly, F., Plantade, A., Paraiso, D., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.183 · Cited by 107
Jankú, F., Kaseb, A. O., Tsimberidou, A. M., Wolff, R. A., & Kurzrock, R. (2014) · Oncotarget · doi:10.18632/oncotarget.1687 · Cited by 100
Self-citationSegrelles, C., Lu, J., Hammann, B. D., Santos, M., Moral, M., Cascallana, J. L., Lara, M. F., Rho, O., Carbajal, S., Traag, J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2564 · Cited by 94
Rexer, B. N., Chanthaphaychith, S., Dahlman, K. B., & Arteaga, C. L. (2014) · Breast Cancer Research · doi:10.1186/bcr3601 · Cited by 93
Huw, L.-Y., O'Brien, C. L., Pandita, A., Mohan, S., Spoerke, J. M., Lu, S., Wang, Y., Hampton, G. M., Wilson, T. R., & Lackner, M. R. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.46 · Cited by 91
Precision medicine: lessons learned from the SHIVA trial
Tsimberidou, A. M., & Kurzrock, R. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00397-6 · Cited by 88
Self-citationPhase II trial of RAD001 and bicalutamide for castration‐resistant prostate cancer
Nakabayashi, M., Werner, L., Courtney, K. D., Buckle, G. C., Oh, W. K., Bubley, G. J., Hayes, J. H., Weckstein, D. J., Elfiky, A. A., Sims, D. M., et al. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11456.x · Cited by 82
Schwaederle, M. C., Elkin, S. K., Tomson, B. N., Carter, J. L., & Kurzrock, R. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1053669 · Cited by 80
Self-citationMolecular Profiling of Infiltrating Urothelial Carcinoma of Bladder and Nonbladder Origin
Millis, S. Z., Bryant, D. H., Basu, G. D., Bender, R. P., Vranić, S., Gatalica, Z., & Vogelzang, N. J. (2014) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2014.07.010 · Cited by 70
Self-citationBesse, B., Leighl, N. B., Bennouna, J., Papadimitrakopoulou, V. A., Blais, N., Traynor, A. M., Soria, J., Gogov, S., Miller, N., Jehl, V., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt536 · Cited by 65
Meyer, D. S., Koren, S., Leroy, C., Brinkhaus, H., Müller, U., Klebba, I., Müller, M., Cardiff, R. D., & Bentires‐Alj, M. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.38 · Cited by 62
Hou, M., Liu, X., Wheler, J. J., Naing, A., Hong, D. S., Coleman, R. L., Tsimberidou, A. M., Jankú, F., Zinner, R., Lu, K. H., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2584 · Cited by 58
Self-citationMechanism of human PTEN localization revealed by heterologous expression in Dictyostelium
Nguyen, H. N., Afkari, Y., Senoo, H., Sesaki, H., Devreotes, P. N., & Iijima, M. (2013) · Oncogene · doi:10.1038/onc.2013.507 · Cited by 58
Wheler, J. J., Moulder, S., Naing, A., Jankú, F., Piha-Paul, S. A., Falchook, G. S., Zinner, R., Tsimberidou, A. M., Fu, S., Hong, D. S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1799 · Cited by 49
Self-citation(2000) · Time to knit · doi:10.1016/j.yonc.2013.04.013 · Cited by 46
Ganesan, P., Jankú, F., Naing, A., Hong, D. S., Tsimberidou, A. M., Falchook, G. S., Wheler, J. J., Piha-Paul, S. A., Fu, S., Stepanek, V. M. T., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0319-t · Cited by 45
Self-citationConconi, A., Raderer, M., Franceschetti, S., Devizzi, L. F., Ferreri, A. J. M., Magagnoli, M., Arcaini, L., Zinzani, P. L., Martinelli, G., Vitolo, U., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12845 · Cited by 42
Wang, M. L., Popplewell, L. L., Collins, R. H., Winter, J. N., Goy, A. H., Kaminski, M. S., Bartlett, N. L., Johnston, P. B., LISTER, J. W., Fanning, S. R., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12780 · Cited by 36
Lee, S. J., Lee, J.-T., Lee, J., Park, Y. S., Park, J. O., Park, Y. S., Lim, H. Y., Kim, K., Do, I., Jung, S., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0022-0 · Cited by 33
The Signature Program: Bringing the Protocol to the Patient
Kang, B., Slosberg, E. D., Snodgrass, S. M., Lebedinsky, C. A., Berry, D., Corless, C., Stein, S., & Salvado, A. J. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.126 · Cited by 27
Rodrigues, H. V., Ke, D., Lim, J. T., Stephen, B., Bellido, J., Jankú, F., Zinner, R., Tsimberidou, A. M., Hong, D. S., Piha-Paul, S. A., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0238-2 · Cited by 16
Self-citationRexer, B. N., Chanthaphaychith, S., Dahlman, K. B., & Arteaga, C. L. (2014) · Apple Academic Press eBooks · doi:10.1201/b17138-4 · Cited by 6
Cited by
Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., et al. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.001 · Cited by 1,486
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
Turner, N. C., Oliveira, M., Howell, S. J., Dalenc, F., Cortes, J., Gomez Moreno, H. L., Hu, X., Jhaveri, K., Krivorotko, P., Loibl, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214131 · Cited by 813
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
Hopkins, B. D., Pauli, C., Du, X., Wang, D. G., Li, X., Wu, D., Amadiume, S. C., Goncalves, M. D., Hodakoski, C., Lundquist, M. R., et al. (2018) · Nature · doi:10.1038/s41586-018-0343-4 · Cited by 706
Cancer-Associated PIK3CA Mutations in Overgrowth Disorders
Madsen, R. R., Vanhaesebroeck, B., & Semple, R. K. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.08.003 · Cited by 276
Targeting ARID1A mutations in cancer
Mullen, J., Kato, S., Sicklick, J. K., & Kurzrock, R. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102287 · Cited by 186
Self-citation
Metadata
- Authors
- Millis, S. Z., Ikeda, S., Reddy, S., Gatalica, Z., & Kurzrock, R.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2016-12-01
- Volume
- 2
- Issue
- 12
- Pages
- 1565
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2463504723
- Cited by
- 315
- References
- 67
- FWCI
- 12.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.